alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[No. 15754-7-III.

Division Three.

November 18, 1997.]

#### The State of Washington, *Respondent,*v. Vicente Loera Reyes, *Appellant.*

Appeal from a judgment of the Superior Court for Yakima County, No. 95-1-01842-0, Robert N. Hackett, J., entered April 22, 1996. *Affirmed*by unpublished opinion per Schultheis, A.C.J., concurred in by Kurtz, J., and Thompson, J. Pro Tern.
### Geology and ground-water resources of the Fairfax quadrangle, Virginia

By: Paul McKelvey Johnston

                            https://doi.org/10.3133/wsp1539L

#### Links

- More information:  **National Geologic Map Database Index Page**                            (html)
-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plates:                               - **Plate 1**                            (pdf)
  - **Plate 2**                            (pdf) 
- Superseded Publications:
                                        Geology of the Great Falls Park area, Fairfax County, Virginia(1956)                                    

- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
§ 520.1248 Levothyroxine. ( a ) *Specifications.* Each tablet contains 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, or 1.0 milligrams (mg) levothyroxine sodium.
( b ) *Sponsors.* See Nos. 059051 and 061690 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer by mouth as follows: ( i ) No. 061690: 0.1 mg/10 pounds (lb) body weight (0.022 mg/kilogram (kg)) as a single dose every 24 hours or as a divided dose every 12 hours.
( ii ) No. 059051: 0.1 mg/10 lb (0.01 mg/lb, 0.022 mg/kg) body weight twice daily.
( 2 ) *Indications for use.* For replacement therapy for diminished thyroid function in dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[81 FR 22523, Apr. 18, 2016, as amended at 86 FR 57996, Oct. 20, 2021]
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA

F OURTH D ISTRICT

HANS KAISER

, Appellant,

v.

STATE OF FLORIDA

, Appellee

.

No. 4D 19

- 3740

[ February 27, 2020 ]

Appeal of order denying rule 3.801 motion from the Circuit Court for

the Seventeenth Judicial Circuit, Broward County ; Martin S. Fein , Judge;

L.T. Case No. 18

- 007050CF10A

.

Hans Kaiser, pro se, Defuniak Springs.

No appearance required for appellee.

P ER C URIAM

.

Affirmed.

G ROSS

, M AY and K LINGENSMITH

, JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
**Exhibit 31.1**
**Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, asAmended**
I, William A. Mitchell, Jr., certify that:
 1.  I have reviewed this quarterly report on Form 10-Q of Front Range Capital Corporation;  2.  Based on my knowledge, this quarterly report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, not misleading withrespect to the period covered by this quarterly report;  3.  Based on my knowledge, the financial statements, and other financial informationincluded in this quarterly report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, and for, theperiods presented in this quarterly report;  4.  The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and we have:
 a.  Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, to ensurethat material information relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this quarterly report is being prepared;  b.  Evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectiveness ofthe disclosure controls and procedures, as of the end of the period covered by thisreport based on such evaluation; and  c.  Disclosed in this report any change in the registrant’s internalcontrol over financial reporting that occurred during the registrant’s most recentfiscal quarter that has materially affected, or is reasonably likely to materiallyaffect, the registrant’s internal control over financial reporting.   Date: May 12, 2005 /s/ William A. Mitchell, Jr.   William A. Mitchell, Jr. Chief Executive Officer
§ 211.48 Plumbing. ( a ) Potable water shall be supplied under continuous positive pressure in a plumbing system free of defects that could contribute contamination to any drug product. Potable water shall meet the standards prescribed in the Environmental Protection Agency's Primary Drinking Water Regulations set forth in 40 CFR part 141. Water not meeting such standards shall not be permitted in the potable water system.
( b ) Drains shall be of adequate size and, where connected directly to a sewer, shall be provided with an air break or other mechanical device to prevent back-siphonage.
[43 FR 45077, Sept. 29, 1978, as amended at 48 FR 11426, Mar. 18, 1983]
Order entered May 3, 2013

In The 

## Court of Appeals **Fifth District of Texas at Dallas**
No. 05
- 13
- 00278
- CV CITY OF DALLAS, Appellant
V.
MILLWEE
- JACKSON JOINT VENTUR E, ET AL., Appellee s On Appeal from the 101st Judicial District Court Dallas County, Te xas Trial Court Cause No. 04
- 07287
- E 

### O RDER
We GRANT appellant’s April 30, 2013 motion for an extension of time to file a brief. Appellant shall file its brief on or before June 12, 2013. We caution appellant that no further extension of time will be gr anted in this accelerated appeal absent extraordinary circumstances.

/s/ CAROLYN WRIGHT CHIEF JUSTICE
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S UNAUDITED FINANCIAL STATEMENTS AS OF AND FOR THE PERIOD ENDING JULY 3,
1999, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS

(In 000's except per share amounts)
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          JAN-01-2000
<PERIOD-END>                               JUL-03-1999
<CASH>                                          28,950
<SECURITIES>                                         0
<RECEIVABLES>                                  107,225
<ALLOWANCES>                                       501
<INVENTORY>                                    289,706
<CURRENT-ASSETS>                               495,106
<PP&E>                                         299,552
<DEPRECIATION>                                  83,469
<TOTAL-ASSETS>                               1,221,148
<CURRENT-LIABILITIES>                          441,421
<BONDS>                                        223,370
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        48,577
<OTHER-SE>                                     408,985
<TOTAL-LIABILITY-AND-EQUITY>                 1,221,148
<SALES>                                      1,289,263
<TOTAL-REVENUES>                             1,289,263
<CGS>                                        1,054,529
<TOTAL-COSTS>                                1,054,529
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              13,314
<INCOME-PRETAX>                                 82,579
<INCOME-TAX>                                    32,200
<INCOME-CONTINUING>                             50,379
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    50,379
<EPS-BASIC>                                       1.04
<EPS-DILUTED>                                     1.02


</TABLE>
<TABLE> <S> <C>



<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF BAB HOLDINGS, INC. FOR THE YEAR ENDED NOVEMBER 30,
1997 AND IS QUALIFIED IN THE ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          NOV-30-1997
<PERIOD-END>                               NOV-30-1997
<CASH>                                         389,896
<SECURITIES>                                         0
<RECEIVABLES>                                2,576,719
<ALLOWANCES>                                   217,000
<INVENTORY>                                    344,424
<CURRENT-ASSETS>                             2,979,192
<PP&E>                                       5,971,601
<DEPRECIATION>                                 882,693
<TOTAL-ASSETS>                              14,627,246
<CURRENT-LIABILITIES>                        4,295,601
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                  1,862,035
<COMMON>                                    10,908,062
<OTHER-SE>                                 (4,115,347)
<TOTAL-LIABILITY-AND-EQUITY>                14,627,246
<SALES>                                      9,846,020
<TOTAL-REVENUES>                            14,240,956
<CGS>                                        3,309,504
<TOTAL-COSTS>                               17,572,095
<OTHER-EXPENSES>                               (3,701)
<LOSS-PROVISION>                               244,232
<INTEREST-EXPENSE>                              74,651
<INCOME-PRETAX>                            (3,402,089)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (3,402,089)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (4,050,286)
<EPS-PRIMARY>                                   (0.55)
<EPS-DILUTED>                                   (0.53)
        



</TABLE>
[Federal Register Volume 75, Number 38 (Friday, February 26, 2010)]
[Notices]
[Pages 8977-8978]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3909]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which

[[Page 8978]]

would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Translational Diabetes and Obesity.
    Date: March 16-17, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Nancy Sheard, SCD, Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 6046-E, MSC 7892, Bethesda, MD 20892, 301-435-
1154, <a href="/cdn-cgi/l/email-protection#43302b262231272d032030316d2d2a2b6d242c35"><span class="__cf_email__" data-cfemail="017269646073656f416272732f6f68692f666e77">[email protected]</span></a>.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; UKGD Member Conflict SEP.
    Date: March 25, 2010.
    Time: 11 a.m. to 1 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Rass M. Shayiq, PhD, Scientific Review Officer, 
Center for Scientific Review, National Institute of Health, 6701 
Rockledge Drive, Room 2182, MSC 7818, Bethesda, MD 20892, (301) 435-
2359, <a href="/cdn-cgi/l/email-protection#f7849f968e9e8685b7948485d9999e9fd9909881"><span class="__cf_email__" data-cfemail="c2b1aaa3bbabb3b082a1b1b0ecacabaaeca5adb4">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: February 18, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-3909 Filed 2-25-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
EX-10.10


 Exhibit 10.10 

[*.*] CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED WITH “[*.*].” AN
UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 FIRST AMENDMENT TO
AMENDMENT TO BRANDED DISTRIBUTOR MARKETING 
 AGREEMENT—MULTI-BRAND 

This First Amendment to Amendment to Branded Distributor Marketing Agreement—Multi-Brand (“Agreement”),
dated effective as of October 1, 2012 (the “Effective Date”), is entered into by and between VALERO MARKETING AND SUPPLY COMPANY, a Delaware corporation (“VMSC”) and GPM INVESTMENTS, LLC
(“Distributor”). 
 RECITALS 

A. VMSC and Distributor entered into an Amendment to Branded Distributor Marketing Agreement - Multi-Brand, dated effective as of
January 1, 2012 (as amended hereby, the “Agreement”), which set forth certain amendments to the Branded Distributor Marketing Agreement (Multi-Brand), dated January 1, 2012 (the
“DMA”). 
 B. VMSC and Distributor now desire to amend the Agreement to add an additional amendment to the DMA on
the terms and conditions set forth herein, to be effective from and after the Effective Date. 
 NOW THEREFORE, in consideration of the
terms, conditions, and covenants set forth in this Agreement, VMSC and Distributor agree as follows: 
 1. Recitals. The foregoing
recitals are true and correct and are incorporated herein. 
 2. Amendment. From and after the Effective Date, a new
Section 23 is added to the Agreement as follows: 
  

23. [*.*]. VMSC agrees that, beginning on October 1, 2012, the provisions of this
section will apply and override any conflicting provisions in VMSC’s [*.*] from time to time. The following capitalized terms have the following meanings: [*.*] means, at a given point in time, the [*.*] under this Agreement, for each [*.*].
[*.*] means each of the following [*.*] listed [*.*] below: [*.*]. 
 For each [*.*], the [*.*]
beginning on October 1, 2012 will be those set forth in the definition of [*.*] above; provided however, that VMSC reserves the right to modify the [*.*] at any time upon 90 days’ written notice to Distributor, so long as the
[*.*]. 

 3. Miscellaneous. 

a. Except as amended hereby, the Agreement remains full force and effect and is hereby ratified and confirmed by the parties.

 b. This Amendment shall be binding on and inure to the benefit of the parties and their permitted successors and assigns.

 c. In the event of a conflict or discrepancy between the terms of this Amendment and the Agreement, this Amendment shall
control. 

  
 Page 1 







 IN WITNESS WHEREOF, the parties hereto have duly executed, sealed, and delivered this Amendment
as of the Effective Date. 
  

									
	 DISTRIBUTOR:
  

GPM INVESTMENTS, LLC
	 		 	 VMSC:
  

VALERO MARKETING AND SUPPLY COMPANY

					
	By:	 	 /s/ Chris Giacabone
	 		 	By:	  	 /s/ David M. Parker

	Name:	 	Chris Giacabone	 		 		  	David M. Parker, Senior Vice President
	Title:	 	COO	 		 		  	


  
 Page 2
§ 556.428 Narasin. ( a ) *Acceptable daily intake (ADI).* The ADI for total residue of narasin is 5 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerance for narasin (marker residue) is: ( 1 ) *Chickens.* Abdominal fat (target tissue): 480 ppb.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See §§ 558.363 and 558.364 of this chapter.
§ 528.2001 *pPL657* recombinant deoxyribonucleic acid construct. ( a ) *Specifications. pPL657* in the *glycoprotein galactosyltransferase alpha-1,3* (*GGTA1*) gene in domestic pigs.
( b ) *Sponsor.* See No. 086134 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Intended use. pPL657* rDNA construct in the *glycoprotein galactosyltransferase alpha-1,3* gene (*GGTA1*) in the lineage of domestic pigs (*Sus scrofa domesticus*) hemizygous and homozygous for the intentional genomic alteration resulting in undetectable endogenous galactose alpha-1,3-galactose sugar residues on biological derivatives of domestic pigs homozygous for the intentional genomic alteration lineage that are intended to be used as sources of food or human therapeutics including excipients, devices, drugs, or biological products.
( 2 ) *Limitations.* Pigs of this lineage (possessing the intentional genomic alteration (*pPL657* rDNA construct)) should not be treated with aminoglycoside drugs and must only be housed in physically contained facilities specified in the approved application.
[86 FR 17064, Apr. 1, 2021]
#### Williams, etc. *v.*McGuire et al.

[No. 17,311.

Filed April 25, 1945.]

*537
      *Anderson, Hicks & Anderson,*of Gary, for appellant.

*C. C. McGiure,*of Gary, for appellees.

Dowell, P. J.

— Appellant sought an appeal to the Lake Circuit Court from a judgment against him in the City Court of Gary, Indiana. More than 30 days having elapsed since the date of the judgment in the latter named court, appellant proceeded under § 5-1006, Burns’ 1933, by filing in the Lake Circuit Court his verified petition for leave to appeal. Thereupon appellees McGuire, Evans and Nichols each filed motions to dismiss the appeal. After hearing evidence the court sustained each of said motions and the appeal was dismissed.

Appellant assigns as errors:

1. The court erred in overruling defendant’s motion for new trial.

2. The court erred in granting the application of Chester C. McGuire for a change of judge.

3. The court erred in permitting the plaintiff Chester

C. McGuire to file a second paragraph of motion to dismiss.

4. The court erred in sustaining the motion of Chester C. McGuire.

5. The court erred in sustaining the second paragraph of plaintiff Chester C. McGuire’s motion to dismiss.

6. The court erred in sustaining the motion of Alex Evans to dismiss appeal.

7. The court erred in sustaining the motion of John D. Nichols to dismiss appeal.

8. The court erred in overruling the oral motion of appellant Lafayette Williams, defendant therein, to 'require the original judgment holder and the assignee of the judgment to elect who will prosecute motion to dismiss appeal.

*538Appellant’s first assignment presents no question. Error asserted upon dismissal of an appeal from a court of inferior jurisdiction, such as that here involved, must be assigned independently. A motion for a new trial is improper. *Tibbetts*v. *O’Connell*(1879), 66 Ind. 171; *Hughes*v. *Chicago, etc., R. Co.*(1912), 50 Ind. App. 278, 98 N. E. 317.

The remaining assignments are discussed in appellant’s brief solely upon the theory that appellees McGuire, Nichols and Evans were not parties in interest below. If this constituted error it was invited by appellant who, by his verified petition for leave to appeal, made appellees parties and brought them into court as such.

Since we have before us no assignment predicating error upon the action of the court below in dismissing the appeal, such action must be sustained.

Affirmed.

Draper, C. J., not participating.

Note. — Reported in 60 N. E. (2d) 609.